Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Amphastar Pharmaceuticals Inc. is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single case constitutes the full extent of the company's current pending portfolio. It is assigned to 1 distinct examiner and a single art unit, which limits the variety of feedback the company receives from the office.
HAGHIGHATIAN, MINA is the busiest examiner for this portfolio. This examiner is responsible for the 1 pending office action currently active. Because the entire workload is concentrated under this individual, the company's immediate patent goals are tied to a single examiner's interpretation of the law. There are no other examiners or art units involved to provide a broader perspective on the technology.
A practitioner must focus their efforts on the specific requirements of HAGHIGHATIAN, MINA. The strategy for this 1 pending office action cannot be generalized, as it is the only case in the Biotechnology & Pharmaceuticals area for this client. Success depends on navigating the specific administrative culture of the single art unit assigned to this case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17975998 | STABLE INJECTABLE EPINEPHRINE FORMULATIONS INCLUDING A METAL-CHELATING AGENT | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17975998 | STABLE INJECTABLE EPINEPHRINE FORMULATIONS INCLUDING A METAL-CHELATING AGENT | HAGHIGHATIAN, MINA | 1616 | §103Other | Non-Final OA | — | Pending | Oct 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmphastar Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mina Haghighatian has the most, with 1 of Amphastar Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.